Media Coverage

Quest Diagnostics recently signed a non-exclusive license agreement with Zora Biosciences Oy, a renowned clinical diagnostics company working to identify robust markers of disease. The agreement is expected to enable Quest Diagnostics in the development of a test service based on Zora's patented ceramide-analysis technology.

With the COVID-19 pandemic accelerating interest in telehealth and consumer-initiated testing, Quest Diagnostics is expanding its existing DTC operation to try to capture $250 million of the emerging market.

Quest Diagnostics' purchase of some lab operations of a St. Louis-based hospital system will bring a positive result for Lenexa. Quest announced this week that it will acquire the outreach laboratory services business of Mercy.

Commercial laboratory Quest Diagnostics Inc. sees a growing direct-to-consumer testing opportunity following the Covid-19 pandemic, as patients seek greater control of their health care and the crisis accelerates a shift to digital technologies.

With the acquisition, Quest will pick up the business from 29 Mercy hospital labs and two independent clinic labs servicing patients and providers throughout Arkansas, Kansas, Missouri, and Oklahoma.